SEC Form 3 · accession 0001209191-19-003282
UroGen Pharma Ltd. · URGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ron Bentsur
Officer — Chief Executive Officer · Director
Period of report
Jan 1, 2019
Accepted (ET)
Jan 10, 2019 · 5:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001668243
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | holding | — | — | — | 38,113 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF2,F1 | — | holding | — | — | — | — | — | Ordinary Shares | 92,768 | — | D |
| Employee Stock Option (right to buy)F3 | $19.55 | holding | — | — | — | — | Jun 28, 2027 | Ordinary Shares | 80,000 | — | D |
| Employee Stock Option (right to buy)F4 | $43.67 | holding | — | — | — | — | Jan 10, 2028 | Ordinary Shares | 50,000 | — | D |
Explanation of responses
- F125% of the restricted stock units ("RSUs") vested on August 9, 2016 and 2.778% of the remaining RSUs will vest in equal monthly installments thereafter.
- F2Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- F38.33% of the shares underlying the stock option will vest in equal quarterly installments commencing 3 months after June 28, 2017.
- F42.778% of the shares underlying the stock option will vest in equal monthly installments commencing 1 month after January 10, 2018.
Remarks
Exhibit List - Exhibit 24 - Power of Attorney